» Articles » PMID: 22717247

Incidence and Significance of Pericardial Effusion in Patients with Pulmonary Arterial Hypertension

Overview
Journal Can J Cardiol
Publisher Elsevier
Date 2012 Jun 22
PMID 22717247
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of pericardial effusion (PEF) during long-term follow-up among patients with pulmonary arterial hypertension (PAH) is unknown. We aimed to determine the incidence and prognostic significance of developing a new PEF among PAH patients.

Methods: Records of consecutive patients diagnosed with PAH between January 1990 and May 2010 were reviewed. Patients had systematically undergone right heart catheterization, transthoracic echocardiography, and coronary angiography during their initial assessment as well as routine echocardiograms during follow-up. Effusions were graded as small (echo-free space in diastole <10 mm), moderate (10-20 mm), or large (≥ 20 mm).

Results: The entire cohort consisted of 154 patients. The prevalence of identified PEF during initial assessment was 28.6%. The incidence of PEF among patients with no effusions who had additional echocardiographic studies during follow-up (n = 102) was 44.1%. Patients who developed PEF during follow-up had no differences with respect to baseline characteristics, associated aetiologies, hemodynamic parameters, and extent of coronary disease. Among these 102 patients, survival estimates were 94.9%, 75.0%, and 62.4% at 1, 3, and 5 years, respectively. Development of a PEF that was at least moderate-sized at its first appearance was a predictor of mortality in univariate (hazard ratio, 6.85; 95% confidence interval, 2.60-18.10) as well as multivariate analysis (hazard ratio, 3.95; 95% confidence interval, 1.26-12.40).

Conclusions: PEF develops frequently in PAH patients. In patients with no PEF at baseline, the appearance of a new moderate-size or larger PEF is associated with increased mortality, whereas no significantly increased mortality was observed when a small PEF develops.

Citing Articles

Is pulmonary hypertension protective against cardiac tamponade? A systematic review.

Adrian R, Alerhand S, Liteplo A, Shokoohi H Intern Emerg Med. 2024; 19(7):1987-2003.

PMID: 38622465 DOI: 10.1007/s11739-024-03566-y.


Diagnostic and prognostic value of echocardiography in pulmonary hypertension: an umbrella review of systematic reviews and meta-analyses.

Dong T, Zhu Q, Wang S, Wang Y, Li G, Kong F BMC Pulm Med. 2023; 23(1):253.

PMID: 37430308 PMC: 10334642. DOI: 10.1186/s12890-023-02552-y.


Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy.

Abu-Rmaileh M, Mirza O, Patel C, Shah T, Hardin E, Bartolome S Pulm Circ. 2023; 13(2):e12226.

PMID: 37063747 PMC: 10103584. DOI: 10.1002/pul2.12226.


Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD.

Zhu T, Wu P, Tan Z, Jin Q, Chen Y, Li L Front Pharmacol. 2023; 14:1124746.

PMID: 36860300 PMC: 9968930. DOI: 10.3389/fphar.2023.1124746.


Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada.

Wijeratne D, Housin A, Lajkosz K, Lougheed M, Xiong P, Barber D Pulm Circ. 2022; 12(1):e12040.

PMID: 35506095 PMC: 9052993. DOI: 10.1002/pul2.12040.